Clinical Trial
Study Details
Enrollment
376
Phase
N/A
Status
COMPLETED
Study ID #
NCT06662825
Study Type
Observational
Summary
This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with patients who had initiated crizanlizumab between 2019 and 2022.
Study Overview
Conditions
Contacts and Locations
Locations
Facility
Novartis Pharmaceuticals
East Hanover, New Jersey 07936
United States
GeoPoint
40.8201, -74.36487